MedImmune, the global biologics research and development arm of AstraZeneca, announced that it has entered into a new five year Scientific and Technological Cooperation Agreement with the São Paulo Research Foundation (FAPESP), an independent public foundation with the mission to foster research and the scientific and technological development of the State of São Paulo in Brazil. This collaboration, which is the result of a cross-functional effort among MedImmune, AstraZeneca Brazil, and the State of São Paulo, will focus on identifying and accessing the best science and scientists in the cardiovascular and metabolic disease areas at São Paulo’s public and private research institutions.
Through the collaboration, the organizations seek to discover scientific breakthroughs in basic and translational research in order to provide a deeper understanding of the pathophysiology of cardiovascular and metabolic diseases and to apply this knowledge towards the development of novel and differentiated medicines for patients.
Through the new agreement, FAPESP will issue a public request for proposals in the cardiovascular and metoabolic disease areas. Selection of any projects will be made by a scientific committee comprised of representatives from both MedImmune and FAPESP. Under the terms of the agreement, the organizations will contribute up to two million dollars each to fund selected research projects over the course of the five year agreement.
In the United States, more than 30 million men who have this cheap levitra prescription sexual debility. No matter what is the nature of your ED trouble, the doctor pills cialis may prescribe any of such medications for treatment. This cialis prices in australia is an unwanted and undesirable scenario which every man and woman wants to overcome at all costs. The ovulation related problems causing viagra no prescription purchasing this infertility issues are: Poor egg qualityHyperprolactinemiaPCOS (polycystic ovary syndrome)Underactive or overactive thyroid glandAIDSCancer Another problem is damage to fallopian tubes due to Pelvic infections, endometriosis, and pelvic surgeries.
“Cardiovasular and metabolic disease is a main therapy area for MedImmune, and we are pleased to enter this exciting new research agreement with FAPESP to find and access some of the most innovative science in the São Paulo area, a region ripe in metabolic expertise and innovation,” said Cristina Rondinone, Vice President and Head of MedImmune’s Cardiovascular and Metabolic Disease (CVMD) Innovative Medicines Unit. “Partnering with academia to identify and qualify new targets and underlying biology is critical in translating discoveries to create innovative new medicines in areas of high unmet medical need.”
“”This agreement allows FAPESP to offer the São Paulo scientific community opportunities to develop research geared toward collaboration with industry. AstraZeneca and MedImmune have substantial investment in basic research and development and value the quality of scientific investigation that exists in São Paulo,” said Carlos Henrique de Brito Cruz, Scientific Director of FAPESP.